## Abstract We conducted a systematic review of the association between HMGโCoA reductase inhibitor (statin) use and cancer risk. We searched MEDLINE, EMBASE, Web of Science, ISI Proceedings and BIOSIS Previews bibliographic databases, electronic trials registers and reference lists for potentially
Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials
โ Scribed by Nathalie Druesne-Pecollo; Paule Latino-Martel; Teresa Norat; Emilie Barrandon; Sandrine Bertrais; Pilar Galan; Serge Hercberg
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- French
- Weight
- 426 KB
- Volume
- 127
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
The effect of betaโcarotene supplementation on cancer incidence has been investigated in several randomized controlled trials. The objective was to review the effect of betaโcarotene supplementation on cancer incidence in randomized trials by cancer site, betaโcarotene supplementation characteristics and study population. Relevant trials were retrieved by searching PubMed (up to April 2009). Authors involved in selected studies were contacted for additional information. Thirteen publications reporting results from 9 randomized controlled trials were included. Overall, no effect of betaโcarotene supplementation was observed on the incidence of all cancers combined (RR, 1.01; 95% CI, 0.98โ1.04), pancreatic cancer (RR, 0.99; 95% CI, 0.73โ1.36), colorectal cancer (RR, 0.96; 95% CI, 0.85โ1.09), prostate cancer (RR, 0.99; 95% CI, 0.91โ1.07), breast cancer (RR, 0.96; 95% CI, 0.85โ1.10), melanoma (RR, 0.98; 95% CI, 0.65โ1.46) and non melanoma skin cancer (RR, 0.99; 95% CI, 0.93โ1.05). The incidence of lung and stomach cancers were significantly increased in individuals supplemented with betaโcarotene at 20โ30 mg day^โ1^ (RR, 1.16; 95% CI, 1.06โ1.27 and RR, 1.34; 95% CI, 1.06โ1.70), in smokers and asbestos workers (RR, 1.20; 95% CI, 1.07โ1.34 and RR, 1.54; 95% CI, 1.08โ2.19) compared to the placebo group. Betaโcarotene supplementation has not been shown to have any beneficial effect on cancer prevention. Conversely, it was associated with increased risk not only of lung cancer but also of gastric cancer at doses of 20โ30 mg day^โ1^, in smokers and asbestos workers. This study adds to the evidence that nutritional prevention of cancer through betaโcarotene supplementation should not be recommended.
๐ SIMILAR VOLUMES
## Abstract ## BACKGROUND Tamoxifen has been used in the treatment of patients with metastatic malignant melanoma either as a single agent or, more commonly, in combination with other chemotherapeutic agents. The aim of the current study was to summarize the available clinical evidence on the role
## Abstract Much debate has focused on whether antioxidants interfere with the efficacy of cancer chemotherapy. The objective of this study is to systematically review the randomized, controlled clinical trial evidence evaluating the effects of concurrent use of antioxidants with chemotherapy on to
## Objectives/Hypothesis To evaluate the existing level of evidence for tinnitus management strategies identified in the UK Department of Health's Good Practice Guideline. ## Study Design Systematic review of peer-reviewed literature and meta-analyses. ## Methods Searches were conducted in PubM
## Abstract Statins have been suggested to prevent prostate cancer. Our aim was to examine statin use in relation to both total prostate cancer and the more clinically important advanced prostate cancer, through a detailed metaanalysis of the epidemiologic studies published on the subject in peerโr